PROMOMED raised 5 billion rubles through the placement of bonds to refinance debt and accelerate the development of innovative drugs.

July 15, 2025, Moscow - PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the successful closing of the application book for exchange–traded bonds of the 002P–02 series in the amount of 5 billion rubles with a maturity of 2 years posted by PROMOMED DM LLC.

PROMOMED DM LLC is a subsidiary of PJSC PROMOMED and the managing organization for the companies of the Group's structure, as well as a trading house for the wholesale of manufactured products and medical supplies.

The volume of the placement amounted to 5 billion rubles, the circulation period – 2 years. The nominal value of the bond is 1,000 rubles, the placement price is 100% of the nominal value. As a result of the collection of applications, the premium to the key rate of the Bank of Russia is fixed at 2.8%, while the coupon will be calculated monthly according to the formula: the key rate of the Central Bank of the Russian Federation + the premium. The bonds are placed under the 002P Series Exchange-Traded Bond Program (4-00560-R-002P-02E dated 03/10/2023).

The Company primarily plans to use the funds raised to refinance public debt and invest in R&D: conducting clinical trials, scaling up the synthesis of active pharmaceutical substances and improving technologies for obtaining dosage forms.

The bonds are included in the 3rd level of the List of securities admitted to trading and are included in the RII sector[1] The Moscow Stock Exchange.

The issue was organized by Alfa-Bank, VTB Capital, Gazprombank, Sber CIB, IFK Solid and Sovcombank.

In June 2025, the rating agency Expert RA confirmed the credit rating of PROMOMED DM LLC at the giA- level. The rating outlook is "Stable".

PROMOMED predicts that in 2025, the ratio of the Group's net debt to adjusted EBITDA over the past 12 months will not exceed 2.5x. As of December 31, 2024, this figure was 2.1x.

Timofey Solovyov, Director of Economics and Finance at PROMOMED PJSC, emphasized: "Rational and timely management of the loan portfolio, creation of an optimal debt structure and duration are all important components of a balanced financial policy of PROMMED. The new bond issue will replace the public debt due in August 2025 and support investments in R&D to implement the forward growth strategy. In Q1 2025, our revenue grew by more than 80%, which confirms the effectiveness of the corporate strategy based on the production of innovative medicines in the fastest growing and marginal segments of the pharmaceutical market."

About the Company

PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market. In 2025, PROMOMED celebrates the 20th anniversary of the Company's founding.

The Company's structure includes its own unique world-class R&D center and a high-tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 350 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of limitation of liability

This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers for the purchase of any securities,
• as part of such offers or invitations,
• securities advertising in the Russian Federation or other jurisdictions,
• an offer to purchase medicines,
• advertising of medicines,
• by encouraging or recommending transactions,
• it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.
The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.

---

[1] Innovation and Investment Market